Tumor-associated antigens in breast cancer

Breast Care

Volumn 7, Issue 4, 2012, Pages 262-266

  Criscitiello, Carmen ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Breast cancer; Tumor antigen; Vaccine

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; IMMUNOGLOBULIN G ANTIBODY; KEYHOLE LIMPET HEMOCYANIN; MUCIN 1; ONCOFETAL ANTIGEN; SIALYLTRANSFERASE; TELOMERASE REVERSE TRANSCRIPTASE; THERATOPE; TUMOR ANTIGEN; WT1 PROTEIN;

ADHESION; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; BREAST CANCER; BREAST METASTASIS; CANCER CELL; CANCER IMMUNOTHERAPY; CANCER REGRESSION; HUMAN; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; MUCOSA; OVARY CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CARCINOMA; REVIEW; SIGNAL TRANSDUCTION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR SUPPRESSOR GENE;

EID: 84866907617     PISSN: 16613791     EISSN: 16613805     Source Type: Journal    
DOI: 10.1159/000342164     Document Type: Review

References (53)

1. Parmiani G, De Filippo A, Novellino L, Castelli C: Unique human tumor antigens: immunobiology and use in clinical trials. J Immunol 2007;178:1975-1979.
2. Parmiani G, Russo V, Marrari A, Cutolo G, Casati C, Pilla L, Maccalli C, Rivoltini L, Castelli C: Universal and stemness-related tumor antigens: potential use in cancer immunotherapy. Clin Cancer Res 2007;13:5675-5679.
3. Curigliano G, Locatelli M, Fumagalli L, Goldhirsch A: Immunizing against breast cancer: a new swing for an old sword. Breast 2009;18(suppl 3):S51-54.
4. Chung MA, Luo Y, O'Donnell M, Rodriguez C, Heber W, Sharma S, Chang HR: Development and preclinical evaluation of a Bacillus Calmette- Guerin-MUC1-based novel breast cancer vaccine. Cancer Res 2003;63:1280-1287.
5. Disis ML, Schiffman K, Guthrie K, Salazar LG, Knutson KL, Goodell V, dela Rosa C, Cheever MA: Effect of dose on immune response in patients vaccinated with an her-2/neu intracellular domain protein-based vaccine. J Clin Oncol 2004;22:1916- 1925.
6. Hodge JW: Carcinoembryonic antigen as a target for cancer vaccines. Cancer Immunol Immunother 1996;43:127-134.
7. Bednarek AK, Sahin A, Brenner AJ, Johnston DA, Aldaz CM: Analysis of telomerase activity levels in breast cancer: positive detection at the in situ breast carcinoma stage. Clin Cancer Res 1997;3:11-16.
8. Stauss HJ, Thomas S, Cesco-Gaspere M, Hart DP, Xue SA, Holler A, King J, Wright G, Perro M, Pospori C, et al.: WT1-specific T cell receptor gene therapy: improving TCR function in transduced T cells. Blood Cells Mol Dis 2008;40:113-116.
9. Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, Mellman I, Prindiville SA, Viner JL, Weiner LM, et al.: The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 2009;15:5323-5337.
10. Banchereau J, Palucka AK: Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 2005;5:296-306.
11. Adema GJ, de Vries IJ, Punt CJ, Figdor CG: Migration of dendritic cell based cancer vaccines: in vivo veritas? Curr Opin Immunol 2005;17:170- 174.
12. Knutson KL, Schiffman K, Disis ML: Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. J Clin Invest 2001;107:477-484.
13. Peethambaram PP, Melisko ME, Rinn KJ, Alberts SR, Provost NM, Jones LA, Sims RB, Lin LR, Frohlich MW, Park JW: A phase I trial of immunotherapy with lapuleucel-T (APC8024) in patients with refractory metastatic tumors that express HER-2/neu. Clin Cancer Res 2009;15:5937- 5944.
14. Kohlgraf KG, Gawron AJ, Higashi M, VanLith ML, Shen X, Caffrey TC, Anderson JM, Hollingsworth MA: Tumor-specific immunity in MUC1.Tg mice induced by immunization with peptide vaccines from the cytoplasmic tail of CD227 (MUC1). Cancer Immunol Immunother 2004;53:1068-1084.
15. Ko BK, Kawano K, Murray JL, Disis ML, Efferson CL, Kuerer HM, Peoples GE, Ioannides CG: Clinical studies of vaccines targeting breast cancer. Clin Cancer Res 2003;9:3222-3234.
16. Ding L, Lalani EN, Reddish M, Koganty R, Wong T, Samuel J, Yacyshyn MB, Meikle A, Fung PY, Taylor-Papadimitriou J, et al.: Immunogenicity of synthetic peptides related to the core peptide sequence encoded by the human MUC1 mucin gene: effect of immunization on the growth of murine mammary adenocarcinoma cells transfected with the human MUC1 gene. Cancer Immunol Immunother 1993;36:9-17.
17. Apostolopoulos V, Xing PX, McKenzie IF: Murine immune response to cells transfected with human MUC1: immunization with cellular and synthetic antigens. Cancer Res 1994;54:5186-5193.
18. Zhang S, Graeber LA, Helling F, Ragupathi G, Adluri S, Lloyd KO, Livingston PO: Augmenting the immunogenicity of synthetic MUC1 peptide vaccines in mice. Cancer Res 1996;56:3315-3319.
19. Acres RB, Hareuveni M, Balloul JM, Kieny MP: Vaccinia virus MUC1 immunization of mice: immune response and protection against the growth of murine tumors bearing the MUC1 antigen. J Immunother Emphasis Tumor Immunol 1993;14: 136-143.
20. Reddish M, MacLean GD, Koganty RR, Kan- Mitchell J, Jones V, Mitchell MS, Longenecker BM: Anti-MUC1 class I restricted CTLs in metastatic breast cancer patients immunized with a synthetic MUC1 peptide. Int J Cancer 1998;76:817- 823.
21. Apostolopoulos V, Pietersz GA, McKenzie IF: Cell-mediated immune responses to MUC1 fusion protein coupled to mannan. Vaccine 1996;14:930- 938.
22. Apostolopoulos V, Loveland BE, Pietersz GA, McKenzie IF: CTL in mice immunized with human mucin 1 are MHC-restricted. J Immunol 1995;155:5089-5094.
23. Apostolopoulos V, Pietersz GA, Loveland BE, Sandrin MS, McKenzie IF: Oxidative/reductive conjugation of mannan to antigen selects for T1 or T2 immune responses. Proc Natl Acad Sci U S A 1995;92:10128-10132.
24. Gilewski T, Adluri S, Ragupathi G, Zhang S, Yao TJ, Panageas K, Moynahan M, Houghton A, Norton L, Livingston PO: Vaccination of highrisk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21. Clin Cancer Res 2000;6:1693-1701.
25. Marshall JL, Gulley JL, Arlen PM, Beetham PK, Tsang KY, Slack R, Hodge JW, Doren S, Grosenbach DW, Hwang J, et al.: Phase I study of sequential vaccinations with fowlpox-CEA(6D)- TRICOM alone and sequentially with vaccinia- CEA(6D)-TRICOM, with and without granulocyte- macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas. J Clin Oncol 2005;23:720-731.
26. Marshall JL, Hoyer RJ, Toomey MA, Faraguna K, Chang P, Richmond E, Pedicano JE, Gehan E, Peck RA, Arlen P, et al.: Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. J Clin Oncol 2000;18:3964-3973.
27. Von Mehren M, Arlen P, Gulley J, Rogatko A, Cooper HS, Meropol NJ, Alpaugh RK, Davey M, McLaughlin S, Beard MT, et al.: The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma. Clin Cancer Res 2001;7:1181-1191.
28. Aarts WM, Schlom J, Hodge JW: Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity. Cancer Res 2002;62:5770- 5777.
29. Rosenberg SA: Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol Today 1997;18:175-182.
30. Vonderheide RH: Telomerase as a universal tumor- associated antigen for cancer immunotherapy. Oncogene 2002;21:674-679.
31. Nair SK, Heiser A, Boczkowski D, Majumdar A, Naoe M, Lebkowski JS, Vieweg J, Gilboa E: Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. Nat Med 2000;6:1011-1017.
32. Vonderheide RH, Domchek SM, Schultze JL, George DJ, Hoar KM, Chen DY, Stephans KF, Masutomi K, Loda M, Xia Z, et al.: Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes. Clin Cancer Res 2004;10:828-839.
33. MacLean GD, Miles DW, Rubens RD, Reddish MA, Longenecker BM: Enhancing the effect of THERATOPE STn-KLH cancer vaccine in patients with metastatic breast cancer by pretreatment with low-dose intravenous cyclophosphamide. J Immunother Emphasis Tumor Immunol 1996;19:309-316.
34. Miles DW, Towlson KE, Graham R, Reddish M, Longenecker BM, Taylor-Papadimitriou J, Rubens RD: A randomised phase II study of sialyl- Tn and DETOX-B adjuvant with or without cyclophosphamide pretreatment for the active specific immunotherapy of breast cancer. Brit J Cancer 1996;74:1292-1296.
35. Sandmaier BM, Oparin DV, Holmberg LA, Reddish MA, MacLean GD, Longenecker BM: Evidence of a cellular immune response against sialyl-Tn in breast and ovarian cancer patients after high-dose chemotherapy, stem cell rescue, and immunization with Theratope STn-KLH cancer vaccine. J Immunother 1999;22:54-66.
36. Holmberg LA, Oparin DV, Gooley T, Lilleby K, Bensinger W, Reddish MA, MacLean GD, Longenecker BM, Sandmaier BM: Clinical outcome of breast and ovarian cancer patients treated with high-dose chemotherapy, autologous stem cell rescue and THERATOPE STn-KLH cancer vaccine. Bone Marrow Transplant 2000;25:1233-1241.
37. Pelletier J, Bruening W, Li FP, Haber DA, Glaser T, Housman DE: WT1 mutations contribute to abnormal genital system development and hereditary Wilms' tumour. Nature 1991;353:431- 434.
38. Hohenstein P, Hastie ND: The many facets of the Wilms' tumour gene, WT1. Hum Mol Genet 2006;15:R196-201.
39. Wagner KD, Wagner N, Schley G, Theres H, Scholz H: The Wilms' tumor suppressor Wt1 encodes a transcriptional activator of the class IV POU-domain factor Pou4f2 (Brn-3b). Gene 2003;305:217-223.
40. Algar E: A review of the Wilms' tumor 1 gene (WT1) and its role in hematopoiesis and leukemia. J Hematother Stem Cell Res 2002;11:589-599.
41. Menssen HD, Renkl HJ, Entezami M, Thiel E: Wilms' tumor gene expression in human CD34+ hematopoietic progenitors during fetal development and early clonogenic growth. Blood 1997; 89:3486-3487.
42. Maurer U, Weidmann E, Karakas T, Hoelzer D, Bergmann L: Wilms tumor gene (wt1) mRNA is equally expressed in blast cells from acute myeloid leukemia and normal CD34+ progenitors. Blood 1997;90:4230-4232.
43. Hosen N, Sonoda Y, Oji Y, Kimura T, Minamiguchi H, Tamaki H, Kawakami M, Asada M, Kanato K, Motomura M, et al.: Very low frequencies of human normal CD34+ haematopoietic progenitor cells express the Wilms' tumour gene WT1 at levels similar to those in leukaemia cells. Brit J Haematol 2002;116:409-420.
44. Wagner KD, Wagner N, Wellmann S, Schley G, Bondke A, Theres H, Scholz H: Oxygen-regulated expression of the Wilms' tumor suppressor Wt1 involves hypoxia-inducible factor-1 (HIF-1). FASEB J 2003;17:1364-1366.
45. Wagner KD, Wagner N, Bondke A, Nafz B, Flemming B, Theres H, Scholz H: The Wilms' tumor suppressor Wt1 is expressed in the coronary vasculature after myocardial infarction. FASEB J 2002;16:1117-1119.
46. Oka Y, Tsuboi A, Kawakami M, Elisseeva OA, Nakajima H, Udaka K, Kawase I, Oji Y, Sugiyama H: Development of WT1 peptide cancer vaccine against hematopoietic malignancies and solid cancers. Curr Med Chem 2006;13:2345-2352.
47. Hernandez-Caballero E, Mayani H, Montesinos JJ, Arenas D, Salamanca F, Penaloza R: In vitro leukemic cell differentiation and WT1 gene expression. Leukemia Res 2007;31:395-397.
48. Fujiki F, Oka Y, Kawakatsu M, Tsuboi A, Nakajima H, Elisseeva OA, Harada Y, Li Z, Tatsumi N, Kamino E, et al.: A WT1 proteinderived, naturally processed 16-mer peptide, WT1(332), is a promiscuous helper peptide for induction of WT1-specific Th1-type CD4(+) T cells. Microbiol Immunol 2008;52:591-600.
49. Tsuboi A, Oka Y, Ogawa H, Elisseeva OA, Li H, Kawasaki K, Aozasa K, Kishimoto T, Udaka K, Sugiyama H: Cytotoxic T-lymphocyte responses elicited to Wilms' tumor gene WT1 product by DNA vaccination. J Clin Immunol 2000;20:195-202.
50. Rosenfeld C, Cheever MA, Gaiger A: WT1 in acute leukemia, chronic myelogenous leukemia and myelodysplastic syndrome: therapeutic potential of WT1 targeted therapies. Leukemia 2003;17:1301-1312.
51. Iiyama T, Udaka K, Takeda S, Takeuchi T, Adachi YC, Ohtsuki Y, Tsuboi A, Nakatsuka S, Elisseeva OA, Oji Y, et al.: WT1 (Wilms' tumor 1) peptide immunotherapy for renal cell carcinoma. Microbiol Immunol 2007;51:519-530.
52. Keilholz U, Letsch A, Busse A, Asemissen AM, Bauer S, Blau IW, Hofmann WK, Uharek L, Thiel E, Scheibenbogen C: A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. Blood 2009;113:6541-6548.
53. Oka Y, Tsuboi A, Taguchi T, Osaki T, Kyo T, Nakajima H, Elisseeva OA, Oji Y, Kawakami M, Ikegame K, et al.: Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci U S A 2004;101:13885- 13890.